PROCYON CORP
PCYN evidence brief
What we can confirm
- BioSniper Score:
- 7.4 / 10
- Market Cap:
- $2.0M
- Lead Asset:
- helix3 bioactive collagen (Approved)
What it means
What to watch
Prepared research question
What matters most for PCYN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PCYN
Procyon Corp (PCYN) is a biotech company focused on wound care with an approved bioactive collagen product (helix3), reporting zero net income and $2.3M in shareholders' equity as of June 30, 2024.
Key risk: No profitability
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.0M
Cash Runway
—
Lead Asset
helix3 bioactive collagen (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2024.
Tracking 1 pipeline candidate for PROCYON CORP.
Procyon Corp (PCYN) is a biotech company focused on wound care with an approved bioactive collagen product (helix3), reporting zero net income and $2.3M in shareholders' equity as of June 30, 2024.
- Procyon Corp's pipeline includes helix3 bioactive collagen for wound care, which is listed as 'Approved' [pipeline].
- The company reported net income of $0.0M and shareholders' equity of $2.3M as of 2024-06-30 [sec].
- The wound care competitive landscape includes 71 competitors, such as M.D. Anderson Cancer Center and Aldeyra Therapeutics [pipeline][competitor_trial].
- Multiple SEC filings (from 2020 to 2023) contain forward-looking statements regarding the company's business and market expectations [sec_mda].
What works
- Procyon has an approved product (helix3 bioactive collagen) in the wound care market, indicating regulatory clearance [pipeline].
- The company's shareholders' equity of $2.3M as of 2024-06-30 provides a modest capital base [sec].
What to weigh
- Procyon reported zero net income as of 2024-06-30, indicating a lack of profitability [sec].
- The wound care market is highly competitive with 71 listed competitors, including larger institutions and companies [pipeline][competitor_trial].
- The company's financial disclosures are limited to forward-looking statements and do not provide detailed operational results in the available chunks [sec_mda].
From the filings
Quoted directly from source documents.
Procyon has an approved wound care product.
“Pipeline Candidate: helix3 bioactive collagen Indication: wound care Phase: Approved”
The wound care market has many competitors.
“Competitive Landscape: 71 competitors: M.D. Anderson Cancer Center (Spinal Sealant, Standard Methods of Closing of the Dura, PHASE3); Marilia Medicine School (Aloe vera gel, PHASE3); Australia and New Zealand Intensive Care Society (Induced Hypothermia, PHASE2/PHASE3); Airway Therapeutics, Inc. (Air-sham, Zelpultide alfa, PHASE2/PHASE3); Apeptico Forschung und Entwicklung GmbH (AP301, Saline solution, PHASE2)”
Risks & what to watch (3)›
Key risks
- No profitability — Net income of $0.0M as of 2024-06-30 indicates the company is not generating profit [sec].
- Intense competition — 71 competitors in wound care, including large institutions and Phase 3 trials, pressure market share [pipeline][competitor_trial].
- Limited financial detail
What to watch
- Any updates on helix3 bioactive collagen sales or market adoption [pipeline].
- Changes in net income or shareholders' equity in future SEC filings [sec].
- New competitive developments or partnerships in the wound care space [pipeline][competitor_trial].
Sources: Competitor trials · Pipeline · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run PROCYON CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PROCYON CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.40
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for PROCYON CORP?
Procyon Corp (PCYN) is a biotech company focused on wound care with an approved bioactive collagen product (helix3), reporting zero net income and $2.3M in shareholders' equity as of June 30, 2024.
What is PROCYON CORP's lead drug candidate?
PROCYON CORP's most advanced tracked candidate is helix3 bioactive collagen (Approved) for wound care.
Who is the CEO of PROCYON CORP?
Mr. Justice W. Anderson is the chief executive officer of PROCYON CORP (PCYN).
Where is PROCYON CORP headquartered?
PROCYON CORP (PCYN) is headquartered in Oldsmar, FL, United States.
What therapeutic areas does PROCYON CORP focus on?
PROCYON CORP develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.